

Loly Tor (loly.tor@klgates.com)
K&L GATES LLP
One Newark Center, 10th Floor
Newark, NJ 07102
(T) 973.848.4026
(F) 973.848.4001

Harold Storey (harold.storey@klgates.com)
(*pro hac vice* application forthcoming)
Elizabeth Weiskopf
(elizabeth.weiskopf@klgates.com)
(*pro hac vice* application forthcoming)
K&L GATES LLP
925 Fourth Avenue, Suite 2900
Seattle, WA 98104
(T) 206.623.7580
(F) 206.623.7022

Anil H. Patel (anil.patel@klgates.com)
(*pro hac vice* application forthcoming)
K&L GATES LLP
609 Main Street, Suite 4150
Houston, TX 77002
(T) 713.815.7300
(F) 713.815.7301

Attorneys for Defendants/Counterclaim-Plaintiffs
Cipla USA, Inc. and Cipla Limited

**IN THE UNITED STATES DISTRICT COURT
DISTRICT OF NEW JERSEY**

TEVA BRANDED PHARMACEUTICAL
PRODUCTS R&D, INC. and NORTON
(WATERFORD) LTD.,

Plaintiffs,

v.

CIPLA USA, INC. and CIPLA LTD.,

Defendants.

Civil Action No. 2:24-cv-07162

Hon. Stanley R. Chesler, U.S.D.J.
Hon. Michael A. Hammer, U.S.M.J.

**FED. R. CIV. P. 7.1 CORPORATE
DISCLOSURE STATEMENT OF CIPLA
LIMITED AND CIPLA USA, INC.**

Document Electronically Filed

Pursuant to Rule 7.1 of the Federal Rules of Civil Procedure, the undersigned counsel for Defendants Cipla Limited and Cipla USA, Inc. (collectively, “Cipla” or “Defendants”), makes the following disclosure statement:

1. Cipla Limited does not have a parent corporation, and no publicly held corporation owns 10% or more of Cipla Limited's stock; and
2. Cipla USA Inc. is a 100% owned subsidiary of InvaGen Pharmaceuticals, Inc., which is a 100% owned subsidiary of Cipla (EU Limited), which is a 100% owned subsidiary of Cipla Limited.

Dated: July 3, 2024

Respectfully submitted,

K&L GATES LLP

By: /s/ Loly G. Tor
Loly G. Tor (loly.tor@klgates.com)
One Newark Center, 10th Floor
Newark, NJ 07102
(T) 973.848.4026
(F) 973.848.4001